- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 12.1 Statement Re: Computation of Ratios
- 23.1 Consent of Ernst & Young LLP
- 31.1 Certification of the Chief Executive Officer Pursuant to Section 302
- 31.2 Certification of the Chief Financial Officer Pursuant to Section 302
- 32.1 Certification of the Chief Executive Officer Pursuant to Section 906
- 32.2 Certification of the Chief Financial Officer Pursuant to Section 906
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-128735, File No. 333-118026, File No. 333-113359, File No. 333-111273, File No. 333-110006 and File No. 333-106602) and in the Registration Statements on Form S-8 (File No. 333-116707, File No. 333-112810, File No. 333-106563, File No. 333-97139, File No. 333-58274, File No. 333-39390, File No. 333-30920, File No. 333-92951, File No. 333-49069, File No. 333-30617, File No. 333-15935, File No. 033-61191, File No. 033-75136, File No. 033-45432, File No. 033-27885, File No. 033-12633, File No. 002-95446, File No. 002-81123 and File No. 002-77846) of our reports dated March 3, 2006, with respect to the consolidated financial statements of Oscient Pharmaceuticals Corporation, Oscient Pharmaceuticals Corporation’s management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Oscient Pharmaceuticals Corporation, included in the Annual Report (Form 10-K) for the year ended December 31, 2005.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 9, 2006